Raloxifene, identified as a novel LSD1 inhibitor, suppresses the migration of renal cell carcinoma

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Ljungberg B, Campbell SC, Cho HY et al. The epidemiology of renal cell carcinoma. Eur. Urol. 60(4), 615–621 (2011).
  MedlineGoogle Scholar
• 2. Ljungberg B, Bensalah K, Canfield S et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur. Urol. 67(5), 913–924 (2015).
  MedlineGoogle Scholar
• 3. Motzer RJ, Jonasch E, Agarwal N et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 15(6), 804–834 (2017).
  MedlineGoogle Scholar
• 4. Zhao W, Qiu Y, Kong D. Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. Acta Pharm. Sinica B 7(1), 27–37 (2017).
  MedlineGoogle Scholar
• 5. Takyar S, Diaz J, Sehgal M, Sapunar F, Pandha H. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials. Anticancer Drugs 27(5), 383–397 (2016).
  Medline CASGoogle Scholar
• 6. Shi Y, Lan F, Matson C et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119(7), 941–953 (2004). •• First article to report LSD1 as a histone lysine-specific demethylase.
  Medline CASGoogle Scholar
• 7. Huang J, Sengupta R, Espejo AB et al. p53 is regulated by the lysine demethylase LSD1. Nature 449(7158), 105–108 (2007).
  Medline CASGoogle Scholar
• 8. Wang J, Hevi S, Kurash JK et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat. Genet. 41(1), 125–129 (2009).
  Medline CASGoogle Scholar
• 9. Ooi SKT, Qiu C, Bernstein E et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448(7154), 714–717 (2007).
  Medline CASGoogle Scholar
• 10. Zhao L-J, Fan Q-Q, Li Y-Y et al. LSD1 deletion represses gastric cancer migration by upregulating a novel miR-142-5p target protein CD9. Pharmacol. Res. 159, 104991 (2020). • Downregulation of LSD1 could repress the migration of gastric cancer through a novel miRNA.
  Medline CASGoogle Scholar
• 11. Ketscher A, Jilg CA, Willmann D et al. LSD1 controls metastasis of androgen-independent prostate cancer cells through PXN and LPAR6. Oncogenesis 3(10), e120–e120 (2014).
  Medline CASGoogle Scholar
• 12. Augert A, Eastwood E, Ibrahim AH et al. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Sci. Signal. 12(567), eaau2922 (2019).
  Medline CASGoogle Scholar
• 13. Hu X, Xiang D, Xie Y et al. LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression. Oncogene 38(44), 7017–7034 (2019).
  Medline CASGoogle Scholar
• 14. Alsaqer SF, Tashkandi MM, Kartha VK et al. Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget 8(43), 73372–73386 (2017).
  MedlineGoogle Scholar
• 15. Zhang J, Zhao D, Li Q et al. Upregulation of LSD1 promotes migration and invasion in gastric cancer through facilitating EMT. Cancer Manag. Res. 11, 4481–4491 (2019).
  MedlineGoogle Scholar
• 16. Boulding T, McCuaig RD, Tan A et al. LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer. Sci. Rep. 8(1), 73 (2018).
  Medline CASGoogle Scholar
• 17. Yang G-J, Lei P-M, Wong S-Y, Ma D-L, Leung C-H. Pharmacological inhibition of LSD1 for cancer treatment. Molecules 23(12), 3194 (2018).
  MedlineGoogle Scholar
• 18. Li ZR, Suo FZ, Hu B et al. Identification of osimertinib (AZD9291) as a lysine specific demethylase 1 inhibitor. Bioorg. Chem. 84, 164–169 (2019).
  Medline CASGoogle Scholar
• 19. Zheng YC, Shen DD, Ren M et al. Baicalin, a natural LSD1 inhibitor. Bioorg. Chem. 69, 129–131 (2016).
  Medline CASGoogle Scholar
• 20. Li Z-R, Suo F-Z, Guo Y-J et al. Natural protoberberine alkaloids, identified as potent selective LSD1 inhibitors, induce AML cell differentiation. Bioorg. Chem. 97, 103648 (2020).
  Medline CASGoogle Scholar
• 21. Liu H-M, Suo F-Z, Li X-B et al. Discovery and synthesis of novel indole derivatives-containing 3-methylenedihydrofuran-2(3H)-one as irreversible LSD1 inhibitors. Eur. J. Med. Chem. 175, 357–372 (2019).
  Medline CASGoogle Scholar
• 22. Sareddy GR, Viswanadhapalli S, Surapaneni P, Suzuki T, Brenner A, Vadlamudi RK. Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway. Oncogene 36(17), 2423–2434 (2017).
  Medline CASGoogle Scholar
• 23. Hoshino I, Akutsu Y, Murakami K et al. Histone demethylase LSD1 inhibitors prevent cell growth by regulating gene expression in esophageal squamous cell carcinoma cells. Ann. Surg. Oncol. 23(1), 312–320 (2016).
  MedlineGoogle Scholar
• 24. Gehling VS, McGrath JP, Duplessis M et al. Design and synthesis of styrenylcyclopropylamine LSD1 inhibitors. ACS Med. Chem. Lett. 11(6), 1213–1220 (2020).
  Medline CASGoogle Scholar
• 25. Chu Y, Xiao Z, Jing N et al. Arborinine, a potential LSD1 inhibitor, inhibits epithelial-mesenchymal transition of SGC-7901 cells and adriamycin-resistant gastric cancer SGC-7901/ADR cells. Invest. New Drugs doi:10.1007/s10637-020-01016-y (2020) (Epub ahead of print).
  Google Scholar
• 26. Li Y, Sun Y, Zhou Y, Li X, Zhang H, Zhang G. Discovery of orally active chalcones as histone lysine specific demethylase 1 inhibitors for the treatment of leukaemia. J. Enzyme Inhib. Med. Chem. 36(1), 207–217 (2021).
  Medline CASGoogle Scholar
• 27. Romussi A, Cappa A, Vianello P et al. Discovery of reversible inhibitors of KDM1A efficacious in acute myeloid leukemia models. ACS Med. Chem. Lett. 11(5), 754–759 (2020).
  Medline CASGoogle Scholar
• 28. Zhu L, Wang J, Kong W et al. LSD1 inhibition suppresses the growth of clear cell renal cell carcinoma via upregulating P21 signaling. Acta Pharm. Sinica B 9(2), 324–334 (2019). •• LSD1 was overexpressed in 52.6% of clear cell renal cell cancer. LSD1 inhibitors could suppress the growth of clear cell renal cell carcinoma via upregulating p21 signaling.
  MedlineGoogle Scholar
• 29. Wu K, Woo SM, Kwon TK. The histone lysine-specific demethylase 1 inhibitor, SP2509 exerts cytotoxic effects against renal cancer cells through downregulation of Bcl-2 and Mcl-1. J. Cancer Prev. 25(2), 79–86 (2020).
  MedlineGoogle Scholar
• 30. Kumar A, Kumari N, Nallabelli N et al. Expression profile of H3K4 demethylases with their clinical and pathological correlation in patients with clear cell renal cell carcinoma. Gene 739, 144498 (2020).
  Medline CASGoogle Scholar
• 31. Wang Y, Liu J, Bai H, Dang Y, Lv P, Wu S. Long intergenic non-coding RNA 00152 promotes renal cell carcinoma progression by epigenetically suppressing P16 and negatively regulates miR-205. Am. J. Cancer Res. 7(2), 312–322 (2017). •• Demonstrated that LSD1 was involved in RCC progression.
  Medline CASGoogle Scholar
• 32. Duan YC, Guan YY, Zhai XY et al. Discovery of resveratrol derivatives as novel LSD1 inhibitors: design, synthesis and their biological evaluation. Eur. J. Med. Chem. 126, 246–258 (2017).
  Medline CASGoogle Scholar